Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812109 | 0.82 | KDM1A (0.40) | KDM1AMAOAMAOBNFE2L2L3MBTL1 | |
| SCHEMBL29796409 | 0.82 | KDM1A (0.40) | KDM1AMAOAMAOBNFE2L2L3MBTL1 | |
| SCHEMBL1338097 | 0.78 | NFE2L2 (0.36) | NFE2L2L3MBTL1ALDH1A1KDM4ETRIM24 | |
| SCHEMBL22326459 | 0.76 | KDM1A (0.46) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL3888983 | 0.76 | HRH1 (0.47) | KDM1AMAOAMAOBL3MBTL1ALDH1A1 | |
| SCHEMBL16352671 | 0.75 | KDM1A (0.36) | KDM1AMAOAMAOBNFE2L2 | |
| SCHEMBL5728737 | 0.75 | L3MBTL1 (0.45) | KDM1AMAOAMAOBL3MBTL1ALDH1A1 | |
| SCHEMBL10116180 | 0.75 | KDM1A (0.43) | KDM1AMAOAMAOBL3MBTL1ALDH1A1 | |
| SCHEMBL3871009 | 0.75 | KDM1A (0.43) | KDM1AMAOAMAOBL3MBTL1ALDH1A1 | |
| SCHEMBL20535018 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | KDM1A 2147/4885MAOA 2314/4885MAOB 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.